Haloperidol (Haldol): uses, mechanism, formulations, and safety

Mechanism of action

Haloperidol’s principal pharmacologic action is antagonism of dopamine D2 receptors in the brain. By reducing dopaminergic activity in the mesolimbic pathway it can reduce positive psychotic symptoms such as delusions and hallucinations. Blockade of D2 receptors in the nigrostriatal and tuberoinfundibular pathways contributes to movement disorders and elevated prolactin levels. Compared with some low‑potency older antipsychotics, haloperidol has relatively little anticholinergic activity. For clinical context and pathophysiology: clinical overview.

Clinical uses and formulations

Indications include schizophrenia (acute and some chronic presentations), acute psychosis, severe manic episodes, agitation in emergency settings, and reduction of tics in Tourette syndrome. Haloperidol is available in multiple formulations: oral tablets and solution, short‑acting intramuscular injections for acute control, and a long‑acting injectable depot (decanoate) for maintenance when adherence is a concern. See treatment guidance: formulation and dosing guidance.

Adverse effects and monitoring

Key safety concerns relate to dopamine blockade and its systemic effects. Common and important adverse effects include:

• Extrapyramidal symptoms (EPS): acute dystonia, parkinsonism and akathisia; often responsive to anticholinergic or antihistaminic medications.
• Tardive dyskinesia: potentially persistent involuntary movements after long‑term exposure; risk may increase with cumulative exposure and age.
• Neuroleptic malignant syndrome (NMS): rare but life‑threatening syndrome with rigidity, fever and autonomic instability.
• Endocrine effects: hyperprolactinaemia can cause menstrual disturbance, sexual dysfunction and bone effects over time.
• Cardiac effects: may prolong QT interval in susceptible patients; use caution with other QT‑prolonging drugs.

Monitoring typically includes assessment for EPS, tardive signs, metabolic parameters when clinically indicated, and ECG in patients with cardiac risk. Drug interactions and practical safety checks are summarized at: safety resources.

Special populations and cautions

Use with caution in elderly patients, particularly those with dementia‑related psychosis, because of increased mortality risk. Pregnancy and breastfeeding require individualized risk–benefit assessment. Adjustments may be needed for hepatic impairment and in combination with other central nervous system depressants.

Clinical considerations

Haloperidol remains in clinical use because of its efficacy, availability in injectable and depot forms, and cost‑effectiveness. However, when long‑term tolerability is a priority, many clinicians consider atypical antipsychotics because of differing side‑effect profiles. Decisions about initiating or continuing haloperidol should weigh the need for rapid symptom control, formulation choice, and the potential for movement, endocrine and cardiac adverse effects.